Podcast appearances and mentions of Amit G Singal

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/early-action-in-hcc-episode-three Overview: This podcast is the third in a three-part series addressing the urgency for early identification and improved care for patients with hepatocellular carcinoma (HCC). In this episode, two experts discuss exciting changes in the HCC treatment landscape, and how primary care providers can help with follow-up and care coordination. Guest: Ghassan Abou-Alfa, MD, MBA & Amit G. Singal, MD, MS

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/early-action-in-hcc-episode-two Overview: This podcast is the second in a three-part series addressing the urgency for early identification and improved care for patients with hepatocellular carcinoma (HCC). In this episode, two experts discuss three HCC patient cases and examine the role of screening and referral in their disease course trajectory. Guest: Ghassan Abou-Alfa, MD, MBA & Amit G. Singal, MD, MS

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh B liver functionSecond-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumabManagement of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitorPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of nivolumab ± ipilimumab and pembrolizumabEmerging immunotherapy combinations currently being investigated in clinical trialsManagement of key adverse events with immune checkpoint inhibitorsPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:http://bit.ly/39V6s72

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications  with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver functionUse of biomarkers to inform treatment for patients with advanced HCCPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72

Audible Article by Amit G. Singal, Joseph K. Lim, and Fasiha Kanwal